David Dukhan
25Patents
9h-index
27Co-inventors
71Inventor score
Filing activity: Nov 13, 2008 → Nov 24, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9109001B2 | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection | Chemistry; Metallurgy | 44 | Active |
| US8362068B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | Chemistry; Metallurgy | 44 | Active |
| US8951985B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | Human Necessities | 31 | Active |
| US9339541B2 | Thiophosphate nucleosides for the treatment of HCV | Emerging Cross-Sectional Technologies | 25 | Active |
| US8742101B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | Chemistry; Metallurgy | 23 | Active |
| US8193372B2 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors | Chemistry; Metallurgy | 21 | Active |
| US9296778B2 | 3′,5′-cyclic phosphate prodrugs for HCV infection | Chemistry; Metallurgy | 18 | Active |
| US9309275B2 | 3′-deoxy nucleosides for the treatment of HCV | Chemistry; Metallurgy | 17 | Active |
| US9403863B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | Chemistry; Metallurgy | 11 | Active |
| US10519159B2 | Antiviral aliphatic ester prodrugs of tenofovir | Emerging Cross-Sectional Technologies | 4 | Active |
| US10030044B2 | Nucleotides for the treatment of liver cancer | Human Necessities | 4 | Active |
| US10449208B2 | Antiviral prodrugs of tenofovir | Human Necessities | 3 | Active |
| US10683321B2 | 4′-or nucleosides for the treatment of HCV | Chemistry; Metallurgy | 2 | Active |
| US10815264B2 | Nucleotides for the treatment of cancer | Human Necessities | 1 | Active |
| US10899788B2 | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases | Chemistry; Metallurgy | 1 | Active |
| US10202411B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | Human Necessities | 1 | Active |
| US11730748B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | Chemistry; Metallurgy | 0 | Active |
| US10736908B2 | Antiviral aryl-amide phosphodiamide compounds | Chemistry; Metallurgy | 0 | Active |
| US10231986B2 | Amino acid phosphoramidate pronucleotides of 2′-cyano, azido and amino nucleosides for the treatment of HCV | Chemistry; Metallurgy | 0 | Active |
| US10238680B2 | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease | Chemistry; Metallurgy | 0 | Active |
| US10005779B2 | 1′,4′-thio nucleosides for the treatment of HCV | Chemistry; Metallurgy | 0 | Active |
| US9187496B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | Chemistry; Metallurgy | 0 | Active |
| US10717758B2 | D-amino acid compounds for liver disease | Chemistry; Metallurgy | 0 | Active |
| US10766917B2 | Nucleotides for the treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US9186369B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.